
Ginkgo Bioworks Holdings, Inc. (DNA)
$
8.79
-0.56 (-6.37%)
Key metrics
Financial statements
Free cash flow per share
-3.3646
Market cap
531.4 Million
Price to sales ratio
2.9425
Debt to equity
0.7554
Current ratio
4.3900
Income quality
0.4883
Average inventory
0
ROE
-0.5355
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ginkgo Bioworks Holdings, Inc., along with its subsidiaries, specializes in developing a platform for cell programming that facilitates the biological production of various products such as novel therapeutics, food ingredients, and petroleum-derived chemicals. The company serves a diverse range of end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. As a testament to its operational performance, the company recorded an operating income of -$559,757,000.00 reflecting its earnings from core operations. The gross profit ratio is 0.83 showcasing the efficiency of the company's production and sales operations, while the gross profit stands at $188,494,000.00 highlighting its profitability from core activities. The company's stock is identified with the symbol 'DNA' in the market, and the operating income ratio is -2.47 indicating the company's operational profitability margin. Additionally, Ginkgo Bioworks has established a partnership with Selecta Biosciences, Inc. to advance the ImmTOR technology platform. Founded in 2008, the company is headquartered in Boston, Massachusetts. In the market landscape, the stock is affordable at $11.37 catering to budget-conscious investors. With a high average trading volume of 1,033,936.00 the stock indicates strong liquidity, making it an appealing option for traders. Ginkgo Bioworks, classified as a small-cap player with a market capitalization of $499,602,152.00 is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth while playing a vital role in shaping future developments in its field.
Investing in Ginkgo Bioworks Holdings, Inc. (DNA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
Analysts predict Ginkgo Bioworks Holdings, Inc. stock to fluctuate between $5 (low) and $17.58 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2026-02-12, Ginkgo Bioworks Holdings, Inc.'s market cap is $499,602,152, based on 56,837,560 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Ginkgo Bioworks Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
To buy Ginkgo Bioworks Holdings, Inc. (DNA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNA. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Ginkgo Bioworks Holdings, Inc.'s last stock split was 1:40 on 2024-08-20.
Revenue: $227,043,000 | EPS: -$10.54 | Growth: -42.62%.
Visit https://www.ginkgobioworks.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $634.56 (2021-11-09) | All-time low: $5 (2025-04-04).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News

seekingalpha.com
Amazon delivered robust Q4 2025 results, with accelerating revenue growth and AWS leading at 23.6% YoY. AMZN's operating margin reached a historic high of 11.8%, driven by strong AWS profitability at a 35% margin. The stock sold off after management guided FY 2026 CapEx to $200bn, 50% above FY 2025 and exceeding operating cash flow by $60bn.

zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.23 at the closing of the latest trading day, reflecting a -9.06% change compared to its last close.

seekingalpha.com
Allegiant Travel Company demonstrates disciplined capacity management and cost control, supporting a "Buy" rating and strong post-earnings stock performance. Q4 2025 results show a swing to profitability with a 10.2% operating margin, despite modest margin compression and reduced unit revenues. ALGT targets stable capacity and efficiency gains in 2026, leveraging Boeing 737 MAX upgrades to drive cost improvements without diluting unit revenues.

zacks.com
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $8.27, denoting a -5.92% move from the preceding trading day.

zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $9.31, signifying a -1.27% move from its prior day's close.

zacks.com
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $10.02, marking a -6.36% move from the previous day.

zacks.com
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.85, indicating a +2.39% shift from the previous trading day.

prnewswire.com
NEW YORK, Jan. 13, 2026 /PRNewswire/ -- MySize, Inc. (NASDAQ: MYSZ), a leading Israeli-based AI-driven fashion technology company, today announced that it is evaluating new opportunities to responsibly monetize its growing portfolio of aggregated and anonymized data intelligence assets. Over time, MySize's platforms have generated large-scale, privacy-compliant insights related to apparel fit trends, sizing mismatches, and product-level performance across brands and retailers.

zacks.com
In the latest trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $9.06, marking a -5.72% move from the previous day.

zacks.com
In the most recent trading session, Ginkgo Bioworks Holdings, Inc. (DNA) closed at $8.31, indicating a +1.96% shift from the previous trading day.
See all news